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Abstract 
Progresses in biology and pharmacology led to highly specific bioactive substances, but their 
poor bioavailability at the site of action is a result of their physico-chemical properties. 
Various design approaches for transport carrier molecules facilitating the cellular entry of 
bioactive substances could help to reach their molecular target in cells and tissues. The 
transfer efficacy and the subsequent pharmacological effects of the cargo molecules are well 
investigated, but the investigations of effects of the carrier molecules themselves on the 
target cells or tissues remain necessary. A special attention should be paid to the differential 
gene expression, particularly in the interpretation of the data achieved by highly specific ac-
tive pharmaceutical products. After application of transmembrane transport peptides, par-
ticularly the pAnt and also the HIV-1 Tat, cells respond with a conspicuous altered gene 
expression of at least three genes. The PKN1 gene was induced and two genes (ZCD1 and 
BSG) were slightly repressed. The genes and the chromosomes are described, the moderate 
differential gene expression graphed, and the ontology is listed. 
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Introduction 
The transport of negatively charged or high mo-
lecular weight agents across the cellular membrane is 
generally highly ineffective; their concentrations at 
the (intracellular) target site tend to be far from opti-
mal. The resulting pharmacological effect is often 
barely detectable, and covered from influences of ad-
ditional surrounding factors.   
To assist nucleic acid-based (= negatively 
charged) or macromolecular therapeutics in travers-
ing the cellular membrane, a number of drug delivery 
systems (viral and non-viral) have been evaluated 
over the years. In principle, virus-based systems har-
bour a great potential due to their high transfer effi-
ciency, and some of them already entered clinical 
evaluation for the treatment of severe genetic disor-
ders, like Cystic Fibrosis (CF) and X-linked severe 
combined immunodeficiency (SCID) [1-6]. The bio-
medical safety hazard associated with viral vectors, 
however, as well as several antigenic and immu-
nological problems, substantially limited the progres-
sion of such “natural” transporters in clinical trials [2, 
7-11].  
To provide an alternative for such effective viral 
transfection agents, significant effort has been put in 
establishing non-viral transporter systems [12], as 
well as in understanding their membrane transloca-Int. J. Med. Sci. 2009, 6 
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tion mechanisms [13-16] and in evaluating the bio-
logical effect of the transported cargo [17-19]. Cur-
rently, the following protein fragments harbour a 
protein transduction domain (PTD) and, are used as 
transport peptides: HIV-1 Tat [17, 20, 21], VP22 [22, 
23], and pAnt, known under the name Penetratin™ 
[24, 25]. An arginine nonamer, the cationic R9 peptide, 
has also capable to facilitate the cellular uptake [26, 
27]. Their physicochemical properties are 
well-documented and their ability to cross cellular 
membranes is beyond controversy [15, 16, 28-31, 31]. 
The pharmacological effects resulting from the appli-
cation of the transport peptides (TPs) themselves, 
however, have not been primarily considered thus far. 
Little is known about their intrinsic pharmacological 
and physiological properties.  
In our lab, gene expression experiments with 
different transport peptides (TP) in HeLa cells stably 
expressing EGFP indicated an increase of EGFP fluo-
rescence upon the application of the transporters 
alone particularly after pAnt application (table 1), 
revealing an unwanted and unexpected gene expres-
sion. Comparative analyses with different concentra-
tions of TPs showed an influence on the behaviour of 
the cells, which may alter the biochemical effect of the 
transported cargo and which could consequently in-
fluence the interpretation of the results. 
Table 1  List of the examined transport peptides. 
The table displays the amino acid sequences of the inves-
tigated transport peptides (TP) and transporter molecules 
used in the study. The synthesis and application are de-
scribed in methods. 
PTD  Amino Acid sequence  Acc. No.: 
HIV-Tat YGRKKRRQRRRC*) P04610 
pAnt RQIKIWFQNRRMKWKKC*) X03790 
TP6287 MTRQTFWHRIKHKC*) Q8ZHK1 
TP6288 KMTRQTWWHRIKHKC*)**) - 
 Polymer   
HPMA N-(2-Hydroxypropyl)-Methacrylamide  - 
*) Single letter code 
**) variant with an additional W 
 
 
For understanding the intrinsic pharmacological 
e f f e c t s  o f  T P s ,  w e  i n v e s t i g a t e d  t o  w h a t  e x t e n t  t h e  
HIV-derived Tat fragment (residues 48-60) and the 
Drosophila-derived antennapedia homeodomain pro-
tein fragment pAnt (residue 43-58) affected gene ex-
pression in HeLa cells. In addition, two novel trans-
membrane transporters termed TP6287 and TP6288 (table 
1), have been included in these analyses. TP6287 and 
TP6288 are peptide fragments derived from the DNA 
sequence of the non-pathogenic Yersina pestis strain 
91001 [32]. As additional controls, the effects of the 
HiPerfect Transfection Reagent (Qiagen, Cat No. 
301704) and of the prototypic polymeric hydrophilic 
N-(2-hydroxypropyl)methacrylamide drug carrier 
(pHPMA) [33-35] were evaluated. With microarray 
technology and quantitative RT-PCR, we assessed the 
transcriptional responses resulting from the incuba-
tion of HeLa cells with the transporter molecules [36].  
Material and Methods 
Peptide Synthesis and Purification 
For solid phase synthesis of the peptides 
RQIKIWFQNRRMKWKK [pAnt43-58] and 
YGRKKRRQRRR [HIV-1 Tat48-60] and 
KKMTRQTWWHRIKHKC [TP6288] and 
KMTRQTFWHRIKHKC [TP6287] we employed the 
Fmoc (9-fluorenyl-methyloxycarbonyl) methodology 
[37, 38] in a fully automated multiple synthesizer 
(Syro II from Multi Syntech Germany). As coupling 
agent 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylu-
roniumhexafluoro-phosphate (HBTU) was used. The 
following side chain protecting groups were em-
ployed: Boc(tert-butyloxycarbonyl) for Lys and Trp, 
Trityl(triphenylmethane) for Gln and Asn and Pbf 
(2,2,4,6,7-Pentamethyldihydrobenzofurane-5-sulfonyl
) for Arg. Fmoc-Lys(Dabcyl) was purchased from 
Merck Biosciences GmbH, Germany. The synthesized 
peptides were cleaved and deprotected from the solid 
support by treatment with 90% trifluoroacetic acid, 
8% tri-isopropyl silane and 2% water (v/v/v/) for 2.5 
h at room temperature. The products were precipi-
tated in ether. The crude material was purified by 
preparative HPLC on a Kromasil 100–10C 18 µm re-
verse phase column (30 × 250mm) using an eluent of 
0.1% trifluoro acetic acid in water (A) and 80% ace-
tonitrile in water (B). The peptide was eluted with a 
successive linear gradient of 10% B to 80% B in 30 min 
at a flow rate of 23 ml/min. The fractions corre-
sponding to the purified protein were lyophilized. 
The purified material was characterized with ana-
lytical HPLC and matrix assisted laser desorption 
mass spectrometry (MALDI-MS). 
Synthesis and characterization of pHPMA 
The HPMA copolymer used in this study was 
described by Lammers [39]. The weight- and num-
ber-average molecular weights (Mw and Mn) and the 
polydispersity (Mw/ Mn) of the copolymer after their 
fractionation (on Superose 4B/6B columns) were de-
termined by size exclusion chromatography on an 
Äkta Explorer (Amersham Biosciences), equipped 
with UV, a differential refractometer (Shodex R-72) 
and a multiangle light scattering detector (DAWN 
DSP-F). The average molecular weights of the co-Int. J. Med. Sci. 2009, 6 
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polymer, which will be further referred to as pHPMA, 
was 31 kD and its polydispersity was 1.3. 
Cell Culture 
Adherent HeLa cells were grown in a 5% CO2 
humidified atmosphere at 37°C and passaged in 
RPMI1640 medium without phenol red, supple-
mented with 10% fetal calf serum (FCS) (Biochrom, 
Germany). For expression profiling studies the cells 
were treated with the different cell penetrating pep-
tides: fragments from Drosophila pAnt43-58 or viral 
HIV-1 Tat48-60, the polymer HPMA or the avirulent 
bacterial fragments ([TP6287 and TP6288] respectively) 
for 1 hour. The TPs were applied to 1 × 106 cells per 
probe. We added 0.1 µl TP (1 mg/ ml) diluted to 100 
µl medium (without FCS) to the HeLa cells in 2 ml 
medium. As a control, cells were transfected using 
HiPerfect Transfection Reagent (Qiagen, Hilden, 
Germany) as proposed by the manufacturer.  
Fluorimeter Measurements 
HeLa cells were stably transfected with a GFP 
mutant (D2-GFP [BD, Clontech]) with 2 hours half 
life. The D2-GFP cells were used to determine the 
relative amount GFP-expression in cells by spectro-
scopic fluorescence measurements. These HeLa 
D2-GFP cells were trypsinized after treatment and 
adjusted to a cell number of 1 million cells per ml with 
Hank´s solution. In each single experiment identical 
cell numbers were used. 
Fluorescence emission spectra measurements 
were accomplished with an SLM-AMINCO 8100 
fluorescence spectrometer (SLM, Urbana, IL) using a 
150 W Xenon lamp. The excitation in the fluorimeter 
was fixed at 475 nm; the emission spectra were 
scanned from 500 to 620 nm with 4  nm monochro-
mator slit width for excitation and emission. Integra-
tion time was 0.2 sec; scan mode was performed at 
fixed High Voltage for photomultiplier (PMT) 1HV = 
1000, for PMT 2HV= 350. The measurements show a 
change of the EGFP gene expression after treatment 
with identical amounts of transporter molecules. The 
estimated relative fluorescence showed a dependence 
on the applied carrier molecules.  
RNA Isolation 
The transporter molecules were applied to the 
culture medium thus was removed after 2h and after 
24 h, cells were washed with Hank´s. The RNA was 
extracted with the Qiagen RNeasy Plus Kit (Qiagen 
Hilden, Germany) briefly as follows: The cells were 
washed twice with Hank´s solution and extracted 
with 1ml of extraction solution. The cells were scraped 
and transferred into micro-centrifuge-tubes, and then 
the cells were homogenized by squeezing though a 
needle 0.9  × 12 mm followed by centrifugation 
through a gDNA-Eliminator column for 30 sec at 
10.000 rpm in the micro centrifuge. An equal volume 
of 70% ethanol was added to the eluate mixed with a 
pipet and applied to the RNeasy spin column. This 
was eluted with 700 µl RW1–buffer by centrifugation 
for 15 sec at 10000 rpm followed by addition of 
RPE-buffer 2 × 500 µl and centrifugation at 10000 rpm 
for 15 sec. Then the column was centrifuged to dry-
ness and eluted by centrifugation with water 
(2 × 30 µl) for 30 sec and 2 min respectively.  
BeadArray gene expression analysis 
We used an integrated genomics profiling and 
computational biology based strategy to identify the 
key genes and gene clusters whose expression are 
altered after exposure to different transmembrane 
TPs. Samples were amplified reversly transcribed 
using 100 ng of total RNA as input material by the 
method of Van Gelder [40]. Amplified RNA synthesis 
was performed using the Illumina®TotalPrep™RNA 
AmplificationKit (Inc., San Diego, CA) following the 
manufacturer’s instructions. Labeling was achieved 
by incorporation of biotin-16-UTP at a ratio of 1:1 with 
unlabeled UTP. Labeled, amplified material (1.25 µg 
per array) was hybridized to the Illumina Human-
Ref-8 v2 BeadChip, (Illumina, Inc., San Diego, CA) 
arrays were scanned with an Illumina BeadArray 
Reader (confocal scanner) and array data were proc-
essed and analyzed with Illumina’s BeadStudio Data 
Analysis Software according the definitions of the 
Illumina’s (ILL) data as well as the ILL annotations.  
Real Time PCR  
Total RNA preparations, as used for chip analy-
sis, were also taken for cDNA synthesis with Roche’s 
Transcriptor High Fidelity cDNA Synthesis Kit. Fol-
lowing the manufacturers instructions 3µg RNA per 
sample were reversely transcribed using an-
chored-oligo(dT)18 primer in 20µl total volume for 30 
minutes at 50°C. The final concentration of the unpu-
rified cDNA was adjusted to 25ng/µl assuming 100% 
efficiency. “No RT” controls (same setup without re-
verse transcriptase) have been prepared for each total 
RNA as well. 
The real-time RT-PCR was carried out in tripli-
cates using a Roche LightCycler 480 system with a 
384-well block and the software version 1.2. The 10µl 
reaction consisted of 25ng of transcribed RNA (1µl), 
1pmol Universal Probe (0.1µl), 50pmol each of for-
ward + reverse primer (0.5µl), water (3.4µl) and 2× 
LightCycler 480 Probes Master mix. The 
PCR-program also was used according to the manu-
facturer’s instructions. “No template controls” and Int. J. Med. Sci. 2009, 6 
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“No RT-controls” (for each cDNA-sample) showed no 
contamination probably affecting the results. The 
normalized ratio was calculated using the Relative 
Quantification module with the 24 hours untreated 
control as “Calibrator”, and the HPRT1 as reference 
gene resulting in individual efficiency of every single 
gene.  
Results and Discussion   
Transfection reagents facilitate the introduction 
of active agents e.g. negatively charged molecules, 
like polyanionic nucleic acids, into target cells, in or-
der to express a therapeutic or a reporter gene. The 
aim is to transfer cargos across cellular membranes in 
a safe and proper way while circumventing and 
avoiding undesired reactions. However, as already 
described in the introduction section, the choice of the 
transfection technology has a slight impact on the 
gene expression of the EGFP reporter in HeLa cells 
(figure 1).   
 
Figure 1  Fluorometric measurements of EGFP expres-
sion. The graph shows the influence of the investigated 
transport carriers on the expression of EGFP in stably 
transfected HeLa cells (relative fluorescence intensity) after 
the incubation time of 72 hours. The peptides [TP6287 ( ); 
TP6288 ( ); pAnt ( ); HIV-Tat ( )] and the polymer 
[pHPMA ( )] were applied in the range of 10 – 1000 ng/µl 
final concentration as described in methods. 
 
This lead us to compare the influence of the 
various transport methods on gene expression. We 
investigated how 5 different molecules and one pro-
totypic polymeric carrier influence a gene expression 
response. At first, we selected a series of induced and 
repressed genes more than twofold, selected by mi-
croarray analysis, which resulted after control with 
RT-PCR in a moderate influence on gene expression. 
The bacterially-originated peptides (TP6287 and TP6288) 
and the virus-derived peptide showed hardly de-
tectable effects on gene expression.  
We found that the pAnt molecule had a little ef-
fect on gene expression and affected the expression of 
19 genes, the HIV-1 Tat peptide the expression of 18 
genes and the two Yersina-derived delivery systems 
TP6287 8 genes and TP6288 7 genes respectively. In ad-
dition, also the copolymer pHPMA, which is known 
to be inert, non-immunogenic and non-toxic, ap-
peared to affect the transcription of 18 genes in HeLa 
cells marginally, but below the subthreshold of 5%. 
These findings suggest that one should realize that the 
implementation of transfection agents and transporter 
molecules have some impact on the gene expression 
patterns, when analyzing the efficacy and the genetic 
consequences of targeted gene therapy in vitro (and in 
vivo). 
Microarray Study 
Differential Gene Expression   
Differential gene expression profiling is rou-
tinely used to detect genes expressed under condi-
tions such as cancer or cellular stress response but 
cannot determine the global players involved in such 
complex phenotypes. Integration of the gene expres-
sion profiling with specific modulation of gene ex-
pression in relevant signalling pathway models can 
identify complex pharmacological functions con-
trolled by the characterized genes. The different qual-
ity controls (QC1-QC5) of the expression analysis us-
ing human Sentrix-8 V2 (1740115221 – 1740115260) 
show a positive gradient hybridization signal re-
sponse, low signals in the stringency controls, a suc-
cessful staining of the test samples, clear negative 
controls and noise, and an expected expression of 
housekeeping genes. The samples were very homo-
geneous (figure 2). The expression study was per-
formed threefold.  
The obtained data proved reliable. The primary 
separation into the defined times points: 2 and 24 
hours exhibit a samples's clustering for the time be-
ing. The probe IDs show no visible change in the gene 
expression 2 hours after treatment with the trans-
porter molecules. The 24 hours probes show a mod-
erately changed gene expression indicated by the 
Pearson correlation as illustrated in figure 2.  
Characteristically up or down regulated genes 
were detected after processing and analyzing with 
Illumina’s BeadStudio Data Analysis Software and are 
described in the following part according the defini-
tions of the Illumina’s (ILL) data as well as of the Il-
lumina’s annotations (table 2). Int. J. Med. Sci. 2009, 6 
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Table 2  Microarray detected genes after treatment with transport peptides. The table lists the up (induced) 
or down regulated (repressed) genes detected by microarray investigations. The left column describes the chromosomal 
locations, the second column the gene symbols, the third the RefSeq accession number. The following six columns describe 
the induction or repression by the different transporter molecules applied. In addition the genes whose gene expression 
shows the most noticeable changes are gray highlighted. The annotations and the corresponding gene maps (left column) are 
listed and show genes differentially expressed (induced = highlighted in red; repressed = highlighted in blue).   
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Figure 2  Correlation data of microarray data after 2 h and 24 h application of the transport peptides. The 
figure shows the graph of the sample correlations of the raw microarray data. The time groups are highly similar. Samples 
split primarily according to time points. Pearson correlation (1-r); r = Pearson correlation coefficient.  
 
 
 
Table 3   Differentially expressed genes analyzed by real-time RT-PCR. The right part of the table lists the 
description of the used primers of the detected regulated genes. The primers for an optimal real-time PCR assay were 
designed by the Universal ProbeLibrary (Roche Diagnostics), Version 2.40 for Human. The lower half of the table shows the 
primers of the used reference genes.  
   RefSeq Primer  Position  Length  GC  [%]  Primer-Sequence 
              
BSG   NM_198589.1  Left  83-102  20  50  gcgaggaataggaatcatgg 
     Right  169-192  24  50  cttctacggtagtgaagactgtgc 
              
PKN1   NM_213560.1  Left  2642-2661  20 50  gaaacagcccttcttcagga 
     Right  2736-2754  19  58  cctcgtcgaagttgctgac 
              
ZCD1   NM_018464.2  Left  134-153  20  55  cagttccagcgtacgagttg 
     Right  190-215  26  35  tttgtaagctagataaccaattgcag 
              
     Reference Genes    
              
G6PD   NM_000402.3  Left  480-499  20 55  gcaaacagagtgagcccttc 
     Right  551-569  19  58  ggccagccacataggagtt 
              
ALAS   NM_000688.4  Left  1867-1889  23  43  catgagacagatgctaatggatg 
     Right  1936-1955  20  45  ttttagcagcatctgcaacc 
              
Hprt1   NM_000194.1  Left  136-159  24  33  tgaccttgatttattttgcatacc 
     Right  218-237  20  55  cgagcaagacgttcagtcct 
              
HMBS   NM_001024382.1  Left  580-597  18 61  tgtggtgggaaccagctc 
     Right  653-671  19  47  tgttgaggtttccccgaat 
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Real-Time RT-PCR Study 
Validation of the Array study 
In the real-time RT-PCR, the different detection 
principle, SYBR-Green-based assays have a much 
higher sensitivity against unspecific products com-
pared to assays based on the Universal Probe Library. 
Up to 3 different primer-probe combinations have 
been calculated for the reference genes using the 
Roche ProbeFinder software version 2.40 (figure 3). 
The performance of each combination has been tested 
by real-time PCR with a dilution series of the control 
RNA covering three orders of magnitude. The com-
bination showing the best linearity and reproducibil-
ity was chosen for further analysis. The also calcu-
lated true PCR efficiency has been later on used to 
increase accuracy of the analysis. The real-time 
RT-PCR was carried out 3-fold to monitor the data 
received from microarrays. 
Bioinformatics Study 
The gene ontology database (GO) describes gene 
products in terms of their associated biological proc-
esses, cellular components and species-independent 
molecular functions, and allows a detailed description 
o f  t h e  a f f e c t e d  g e n e s .  G O  t e r m s  ( G O :  
http://www.geneontology.org/) of the differentially 
expressed genes are shown in table 4.  
 
 
Figure 3. Comparison of the expression level of the 
reference genes. The main modified genes (grey in table 
2) and the reference genes used are listed. The graph dis-
plays the relative expression level of the used reference 
genes (  HPRT;  ALAS;  G6PD;  HMBS) in 
quantitative RT-PCR. The ordinate represents the corre-
sponding concentration ratio relative to reference genes; 
the abscissa represents the investigated transporter 
molecules and the corresponding control. The maximized 
synchronous curve linearity or the conformity of the bun-
dles of the columns is ideal. The HMBS (NM_001024382.1) 
was used as a further internal control. 
 
Table 4   Description of the location and known function of the three mainly affected genes. The table lists 
the up- (induced, red) or down-regulated (repressed, blue) genes detected. The left column describes the chromosomal 
locations, the second column the gene symbols, the third the accession number. The following six columns describe the 
induction or repression by the different transporter molecules applied and indicated on top. The two columns on the right 
side depict the gene ontology category.  
 
 
 
 
In these analyses, we identified two chromo-
somes (10 and 19) with altered gene expression (table 
2 [gray highlighted]). The pAnt treated probe shows 
mainly three genes which are differentially expressed 
(the induced expression of PKN1; and the repressed 
genes ZCD1 and BSG compared to the expression of 
three house-keeping genes, listed in table 4), whereas 
all the other transporter molecules reveal hardly ob-
servable differences of gene expression. The signifi-
cance-determinations are listed in figure 4. Int. J. Med. Sci. 2009, 6 
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Figure 4  Induction and repression of the three 
validated genes (A, B, C). The graphs display the results 
of the quantitative PCR of the differential gene expression 
related to the HPRT1 gene in HeLa cells 24h after treat-
ment; the abscissae show the investigated transporter 
peptides ( pAnt,  HIV-TAT,  TP
6287, TP
6288, 
HiPerfect transfection tool, and the  pHPMA polymer); 
the ordinates represent the linear ratio of differential gene 
expression. 
 
Genes detected and in following investigated for valida-
tion 
A) an induced expression of the PKN1 gene 
B) a repressed expression of the ZCD1 gene 
C) a repressed expression of BSG gene 
 
Gene locus 10q21.1 on the long arm of the chromo-
some  
In HeLa cells, we found a moderate repression of 
the ZCD1 after pAnt treatment (figure 4B). The official 
full name of ZCD1 ( CISD1) gene is registered as 
CDGSH iron sulfur domain 1 and it is a member of the 
CDGSH domain-containing family 
(http://amigo.geneontology.org/cgi-bin/amigo/sea
rch.cgi?action=query&view=query&query=ZCD1&se
arch_constraint=gp). The role of this outer mitochon-
drial membrane protein (GO:0005739) seems to be 
crucial in the regulation of mitochondrial oxidative 
capacity [41]. Iron ion proteins (GO:0005506) are con-
sidered as key players in vital processes involving 
energy homeostasis and metabolism in many organ-
isms [42]. The fact that the search in the NCBI data-
base PubMed still shows only a few hits accentuates 
the need of further investigations. Particularly a better 
understanding of the influence of the molecular func-
tion is necessary, as well as of biochemical processes 
and of the biophysical properties provoked amongst 
others by a moderate repression of the gene expres-
sion.  
Gene locus 19p13 on the short arm of the chromosome 
It is coincidence that the detected genes, the 
PKN1 and BSG gene cluster on the adjacent chromo-
somal location: 
The gene expression data show that the short 
arm of the chromosome 19p13.1-p12 represents the 
gene locus of the PKN1  (Figure 4A),  induced after 
treatment with pAnt and HIV-Tat carrier molecules, 
in which the pAnt treated probe shows increased gene 
expression compared to the HIV-1 Tat probe.  
The PKN1 protein kinase N1 is a transcript 
variant 1 encoded by PKN. Its cytoplasmic gene 
product is a serine/threonine-protein kinase N1 
which is a member of the protein kinase C superfam-
ily (http://amigo.geneontology.org/cgi-bin/amigo/
gp-details.cgi?gp=UniProtKB:Q16512). The prote-
olytic activation of this kinase is reported und sug-
gests its role mediating insulin signals to the actin 
cytoskeleton [43]. Gene ontology biological process 
data exhibit a non tissue-specific expression 
(GO:0005737) of PKN1 and an activation of JNK ac-
tivity (GO:0007257).  
On the short arm of the chromosome 19q13.3 we 
also detected a gene locus harbouring the BSG gene, 
which is repressed solely after treatment with pAnt 
whereas the other probes of tested transporter mole-
cules do not show a perceivable effect (Figure 4C). 
The ontology of the BSG gene product is a cell mem-Int. J. Med. Sci. 2009, 6 
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brane localized single-pass type I membrane protein 
(GO:0005886). This basigin protein (BSG) is a cell 
surface receptor protein linked to signal transduction 
(CD147) (GO:0007166). The basigin protein was 
shown to be present in vascular endothelium in both 
in the non-neoplastic region of the brain and in tumor 
cells. (http://amigo.geneontology.org/cgi-bin/amig
o/gp-details.cgi?gp=UniProtKB:P35613). Data sug-
gest its possible involvement in tumor progression 
[44] and in the progression of acute lymphoblastic 
leukemia [45]. The BSG is also involved in the modu-
lation of the angiogenic capability of endothelial cells 
[46] (UniProtKB/Swiss-Prot P35613). The correlation 
of the BSG expression with malignant potential of the 
tumor led to its use as a prognostic factor in radio-
therapy of cervical cancer [47]. 
Conclusion and Remarks 
Being involved in a variety of physiological and 
pathological activities, our results demonstrate can-
didates for continuative investigations. It could be 
clarified, to which extent a slight modulation of a 
sensible gene regulation would generate an alteration 
of the cellular phenotype as demonstrated using the 
expression of the GFP reporter gene.  
We show here that not only the experimental 
design of active cargos but also the choice of the TPs 
could influence differentially regulated genes, and as 
a consequence create unexpected and undesired reac-
tions. The question to what extent a moderate aber-
rant gene expression could contribute to a change of a 
cellular phenotype still remains to be answered. The 
preparation of these differential gene expression pro-
files, performed by sensitive procedures at the gene 
transcription level like microarray studies and simul-
taneously validated by Real Time RT-PCR, holds 
great promise for rapid host genome functional 
analysis. It is plausible that in host cells expression 
profiling after treatment with active agents or as a 
consequence of infections may generate a new phe-
notype in affected cells. Here, we described the effect 
of different carrier molecules used for the facilitated 
transport into target cells:  
Our data suggest that the gene expression can 
depend on the choice of the used reagent facilitating 
the transport of substances across the cell membrane, 
and we realized an impact on the experimental out-
comes like undesired target-effects which can lead to 
misinterpretation of pharmacological effects. In order 
to minimize off-target effects and interpretation of 
results, perhaps these findings could contribute to a 
better interpretation of gene expression data, a better 
choice of suitable individual strategies for the intro-
duction of nucleic acids and its derivatives, as well as 
functional peptides as drugs or markers into target 
cells and tissues. 
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